Physician

Andrew Scott Mener, M.D.

According to 2025 Medicare claims, Andrew Mener, M.D. (NPI: 1891084513) practices hematology in the Baltimore-Columbia-Towson, MD market, with the plurality of this provider's patient population coming from Howard, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY P.A. (NPI: 1396710703; TIN: 113652573) and primary practice location at 21044-3257.

Mener's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,048 traditional Medicare patients, billed 321,174 HCPCS/CPT codes, and received $5,860,316 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,089 prescription claims across 202 beneficiaries totaling $5,857,245 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 44 claims. Open Payments data shows 99 records totaling $124,383. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,054,015 to $5,860,316. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,993 to $5,857,245. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	410	114,199	$1,054,015
2018	867	323,935	$3,110,652
2019	927	322,027	$3,640,781
2020	721	254,949	$3,280,214
2021	774	292,244	$3,211,484
2022	809	320,609	$3,389,410
2023	900	332,939	$5,113,170
2024	1,048	321,174	$5,860,316

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	15	23	$3,993
2017	45	114	$401,840
2018	108	492	$1,868,463
2019	116	612	$2,003,869
2020	118	545	$2,320,234
2021	115	599	$2,763,307
2022	119	579	$3,516,686
2023	166	745	$3,075,891
2024	202	1,089	$5,857,245

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	14	$4,331
2019	N/R	23	$2,571
2020	N/R	39	$3,073
2021	24	111	$7,790
2022	11	70	$2,620
2023	N/R	31	$7,665
2024	N/R	44	$1,365

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	649	1,117	$74
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	330	625	$13
80053	Blood test, comprehensive group of blood chemicals	677	2,788	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	686	3,210	$8
83615	Lactate dehydrogenase (enzyme) level	335	824	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	40	1,260	$957,510
Revlimid	Lenalidomide	52	1,456	$917,512
Lenalidomide	Lenalidomide	59	1,652	$852,631
Brukinsa	Zanubrutinib	63	1,890	$831,089
Tagrisso	Osimertinib Mesylate	31	930	$536,173

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	23	$969
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	21	$395

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	75	$2,186	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	24	$122,198	Daiichi Sankyo Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Scott Mener, M.D.?

Tedicare shows public-source Medicare data for Andrew Scott Mener, M.D. (NPI 1891084513), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Scott Mener, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew Scott Mener, M.D.?

Andrew Scott Mener, M.D. is linked to MARYLAND ONCOLOGY HEMATOLOGY P.A. (billing NPI 1396710703) in the available physician profile data.

Does Andrew Scott Mener, M.D. have Open Payments data?

Andrew Scott Mener, M.D. has 99 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.